Insmed Falls On Mixed Results For Lung Drug
Biotech Insmed (INSM) said a phase-two trial of its lung-infection drug Arikayce failed to meet its primary endpoint but met its secondary endpoint, sending the stock down 12% in heavy midday trading on the stock market today. The pre-specified endpoint of the trial was a certain reduction in the density of mycobacteria on day 84 of the trial. Insmed said that patients in the Arikayce group didn’t meet that endpoint significantly more often than